➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Express Scripts
Boehringer Ingelheim
Colorcon
Medtronic

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Rituximab; hyaluronidase (human recombinant) - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for rituximab; hyaluronidase (human recombinant)

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
National Cancer Institute (NCI)Phase 2
Academic and Community Cancer Research UnitedPhase 2

See all rituximab; hyaluronidase (human recombinant) clinical trials

Recent Litigation for rituximab; hyaluronidase (human recombinant)

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Alvotech hf.2021-04-27
ABBVIE INC. v. DR. REDDY'S LABORATORIES, INC.2020-07-22
Genentech, Inc. v. Samsung Bioepis Co. Ltd.2020-06-28

See all rituximab; hyaluronidase (human recombinant) litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2021-09-24
Fresenius Kabi USA, LLC2021-08-18
Celltrion, Inc.2018-05-04

See all rituximab; hyaluronidase (human recombinant) litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rituximab; hyaluronidase (human recombinant) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rituximab; hyaluronidase (human recombinant) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for rituximab; hyaluronidase (human recombinant) Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for rituximab; hyaluronidase (human recombinant)

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1035 Netherlands ⤷  Free Forever Trial PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218
C1033 France ⤷  Free Forever Trial PRODUCT NAME: POLATUZUMAB VEDOTIN; REGISTRATION NO/DATE: EU/1/19/1388 20200120
2015017,C2201840 Lithuania ⤷  Free Forever Trial PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
AstraZeneca
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.